BUZZ-U.S. STOCKS ON THE MOVE-Sarepta, Sprint, KaloBios, Gap
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock indexes rose on Friday, with the S&P 500 on track for its best week in a year, as healthcare and consumer stocks rose. The Dow Jones industrial average was up 0.59 percent at 17,836.54, the S&P 500 was up 0.45 percent at 2,090.58 and the Nasdaq Composite was up 0.50 percent at 5,099.213.
** BIOMARIN PHARMACEUTICAL INC, $99.38, -3.62 pct
** SAREPTA THERAPEUTICS INC, $34.61, +32.76 pct
** PTC THERAPEUTICS INC, $27.9, -7.37 pct
U.S. Food and Drug Administration staff reviewers said clinical data to date did not merit approving the drug developer's muscle-wasting disorder drug.
Shares of Sarepta, which is developing rival product for DMD, rose. Shares of PTC, whose experimental DMD drug has also failed a late-stage study, fell.
** SPRINT CORP, $3.805, -6.05 pct Continued...